clovis oncology inc (CLVS:NASDAQ GS)

Executive Profile*

Background*

Dr. Thorlef Spickschen is the Chairman of Investors Committee at Heidelberg Innovation Gruppe, Heidelberg Innovation BioScience Venture II GmbH & Co. KG, L.P., and the Vice Chairman of BioVisioN AG. Dr. Spickschen has been a Director of Weston Medical Group PLC since January 2002 and December 2001. In addition to Weston Medical, he also serves on the Board of several academic and social institutions. Dr. Spickschen has been a Director of Pharmion Corp. since December ... 2001. Dr. Spickschen is on the Board of Cytos Biotechnology AG. He also serves on the Boards of several privately held companies in Europe and the United States. Dr. Thorlef Spickschen served as the Chairman and Chief Executive Officer of BASF Pharma/ Knoll AG. In 1994, he joined BASF and became Chief Executive Officer of the pharmaceutical division, until the takeover by Abbott in 2001. From 1976 to 1984, Dr. Spickschen was the General Manager and Managing Director, Germany, and Central Europe for Eli Lilly & Co. Earlier in his career, he also held business positions at McKinsey & Company. Dr. Spickschen was the Member of Executive Management of Boehringer Mannheim in 1985 assuming responsibility for sales. Dr. Spickschen has worked as a Senior Executive in the pharmaceutical industry for over 30 years. Between 1990 and 1993, Dr. Spickschen was the Chairman of the Executive Management of Boehringer Mannheim and between 1992 and 1993; a Member of the Executive Board of Corange Ltd. He served as a Director of United Biscuits Holdings PLC from 1992 to 2000, GFK AG, and EpiCept Corporation since November 2001. Among other things, Dr. Spickschen was active for many years on the Executive Board of the Verband Forschender Arzneimittelhersteller and on the EFPIA Board (European Federation of Pharmaceutical Industries and Associations). Dr. Spickschen received a Doctorate in Business Management from the University of Cologne.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
CLVS:US	$35.80 USD	+0.175

COMPETITOR COMPENSATION